Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial

Autor(es):Mostrar menos -

Lopes, Maria Isabel ^[1] ; Bonjorno, Leticia P. ^[1] ; Giannini, Marcela C. ^[1] ; Amaral, Natalia B. ^[1] ; Menezes, Pamella Indira ^[1] ; Dib, Saulo Musse ^[1] ; Gigante, Samara Libich ^[1] ; Benatti, Maira N. ^[1] ; Rezek, Uebe C. ^[1] ; Emrich-Filho, Laerte L. ^[1] ; Sousa, Betania A. A. ^[1] ; Almeida, Sergio C. L. ^[1] ; Assad, Rodrigo Luppino ^[1] ; Veras, Flavio P. ^[2] ; Schneider, Ayda ^[2] ; Rodrigues, Tamara S. ^[3] ; Leiria, Luiz O. S. ^[2] ; Cunha, Larissa D. ^[3] ; Alves-Filho, Jose C. ^[2] ; Cunha, Thiago M. ^[2] ; Arruda, Eurico ^[3] ; Miranda, Carlos H. ^[4] ; Pazin-Filho, Antonio ^[4] ; Auxiliadora-Martins, Maria ^[5] ; Borges, Marcos C. ^[4] ; Fonseca, Benedito A. L. ^[1] ; Bollela, Valdes R. ^[1] ; Del-Ben, Cristina M. ^[6] ; Cunha, Fernando Q. ^[2] ; Zamboni, Dario S. ^[3] ; Santana, Rodrigo C. ^[1] ; Vilar, Fernando C. ^[1] ; Louzada-Junior, Paulo ^[1] ; Oliveira, Rene D. R. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Internal Med, Ribeirao Preto - Brazil

^[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pharmacol, Ribeirao Preto - Brazil

^[3] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Cell Biol, Ribeirao Preto - Brazil

^[4] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Emergency Med, Ribeirao Preto - Brazil

^[5] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Surg & Anat, Ribeirao Preto - Brazil

^[6] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav, Ribeirao Preto - Brazil

• Tipo de documento: Artigo Científico
• Fonte: RMD OPEN; v. 7, n. 1 2021.
• Citações Web of Science: 1

Resumo

Objective To evaluate whether the addition of colchicine to standard treatment for COVID-19 results in better outcomes. Design We present the results of a randomised, double-blinded, placebo-controlled clinical trial of colchicine for the treatment of moderate to severe COVID-19, with 75 patients allocated 1:1 from 11 April to 30 August 2020. Colchicine regimen was 0.5 mg thrice daily for 5 days, then 0.5 mg twice daily for 5 days. The primary endpoints were the need for supplemental oxygen, time of hospitalisation, need for admission and length of stay in intensive care unit and death rate. Results Seventy-two patients (36 for placebo and 36 for colchicine) completed the study. Median (and IQR) time of need for supplemental oxygen was 4.0 (2.0-6.0) days for the colchicine group and 6.5 (4.0-9.0) days for the placebo group (p<0.001). Median (IQR) time of hospitalisation was 7.0 (5.0-9.0) days for the colchicine group and 9.0 (7.0-12.0) days for the placebo group (p=0.003). At day 2, 67% versus 86% of patients maintained the need for supplemental oxygen, while at day 7, the values were 9% versus 42%, in the colchicine and the placebo groups, respectively (log rank; p=0.001). Two patients died, both in placebo group. Diarrhoea was more frequent in the colchicine group (p=0.26). Conclusion Colchicine reduced the length of both, supplemental oxygen therapy and hospitalisation. The drug was safe and well tolerated. Once death was an uncommon event, it is not possible to ensure that colchicine reduced mortality of COVID-19. (AU)

• Processo FAPESP: 13/08216-2 - CPDI - Centro de Pesquisa em Doenças Inflamatórias
• Beneficiário: Fernando de Queiroz Cunha
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs
• Processo FAPESP: 20/05601-6 - Neutrophil extracelular traps (NETs): importância na patogênese e potencial alvo terapêutico na COVID-19
• Beneficiário: Fernando de Queiroz Cunha
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 20/05288-6 - O papel da eferocitose no dano tecidual e hiperinflamação na infecção por SARS-CoV-2
• Beneficiário: Larissa Dias da Cunha
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 20/04964-8 - Ativação do inflamassoma pelo SARS-CoV-2 e o papel dessa plataforma na patogênese do COVID-19: estudo prospectivo visando inibição de NLRP3 para tratamento da COVID-19
• Beneficiário: Dario Simões Zamboni
• Modalidade de apoio: Auxílio à Pesquisa - Regular